Monopar Therapeutics (MNPR) Share-based Compensation: 2017-2020
Historic Share-based Compensation for Monopar Therapeutics (MNPR) over the last 4 years, with Sep 2020 value amounting to $283,713.
- Monopar Therapeutics' Share-based Compensation rose 16.78% to $283,713 in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year increase of 30.91%. This contributed to the annual value of $4.6 million for FY2024, which is 139.86% up from last year.
- Per Monopar Therapeutics' latest filing, its Share-based Compensation stood at $283,713 for Q3 2020, which was down 22.77% from $367,358 recorded in Q2 2020.
- In the past 5 years, Monopar Therapeutics' Share-based Compensation registered a high of $367,358 during Q2 2020, and its lowest value of $43,926 during Q3 2017.
- In the last 3 years, Monopar Therapeutics' Share-based Compensation had a median value of $242,956 in 2019 and averaged $230,006.
- Data for Monopar Therapeutics' Share-based Compensation shows a peak YoY increase of 268.72% (in 2018) and a maximum YoY decrease of 55.29% (in 2018) over the last 5 years.
- Monopar Therapeutics' Share-based Compensation (Quarterly) stood at $63,189 in 2017, then spiked by 268.72% to $232,992 in 2018, then rose by 18.80% to $276,805 in 2019, then grew by 16.78% to $283,713 in 2020.
- Its last three reported values are $283,713 in Q3 2020, $367,358 for Q2 2020, and $338,497 during Q1 2020.